How is Multidrug-Resistant TB (MDR-TB) Treated?
At a Glance
Multidrug-resistant tuberculosis (MDR-TB) is highly curable with modern, six-month, all-oral treatments like the BPaL and BPaLM regimens. These pill-based treatments have replaced older, injection-heavy methods, offering much higher success rates with fewer severe side effects.
In this answer
4 sections
If the standard six-month tuberculosis (TB) antibiotics do not work, it usually means the bacteria causing your infection have developed resistance to the drugs. If your TB is resistant to at least isoniazid and rifampin (the two most powerful first-line TB drugs), it is known as multidrug-resistant tuberculosis (MDR-TB). While hearing that you have a resistant strain can be frightening and isolating, the most important thing to know is that MDR-TB is highly curable. The treatment landscape has dramatically improved in recent years, shifting from years-long regimens with severe side effects to shorter, much more manageable all-oral (pill-based) treatments [1][2].
The Shift Away From Daily Injections
Historically, treating MDR-TB required up to two years of medication, including painful daily injections of drugs like amikacin. These injectable medications were difficult to endure and were often associated with severe, permanent side effects, including irreversible hearing loss [3][4].
Today, medical guidelines strongly recommend replacing these injectable agents with all-oral short-course regimens. This transition has not only made treatment more tolerable but has also improved overall success rates [4][5]. The focus is now on patient-centered care, emphasizing regimens that are easier to stick with and less disruptive to daily life [6][7].
The Breakthrough: BPaL and BPaLM Regimens
The biggest breakthrough in MDR-TB treatment is the development of the BPaL and BPaLM regimens. These are six-month, all-oral treatments that have shown superior success rates compared to older, long-term options [1][2].
- BPaLM Regimen: This combines four drugs: bedaquiline, pretomanid, linezolid, and moxifloxacin. It is currently the preferred treatment for most patients with MDR-TB [8][9]. Bedaquiline acts as a highly effective core drug, helping you get better faster and ensuring the TB does not come back [10][11].
- BPaL Regimen: If your TB strain is also resistant to fluoroquinolones (like moxifloxacin)—a condition sometimes referred to as pre-extensively drug-resistant TB (pre-XDR-TB)—the three-drug BPaL regimen (bedaquiline, pretomanid, and linezolid) is used. It remains a remarkably powerful option, with real-world studies showing treatment success rates as high as 98% [12].
Managing Side Effects and Your Daily Routine
While these modern treatments are much better tolerated, they still require active monitoring. Linezolid, one of the key drugs, can cause side effects like peripheral neuropathy (tingling or numbness in the hands and feet) and myelosuppression (a decrease in bone marrow activity, leading to conditions like anemia) [12][13].
To minimize these risks, doctors now use optimized dosing. A major clinical trial demonstrated that a daily linezolid dose of 600 mg provided the best balance—curing the TB while significantly reducing the occurrence of nerve damage and low blood counts [14]. If side effects do occur, your medical team will proactively manage them, which might involve adjusting the dose of linezolid or occasionally pausing the medication [15][16].
Because treatment involves powerful medications, you can expect a rigorous monitoring schedule. Regimens containing bedaquiline require routine ECG (electrocardiogram) monitoring to ensure your heart rhythm remains safe [17][18].
The Importance of Adherence: Even though these new regimens are shorter and all-oral, it is absolutely critical to take every dose exactly as prescribed. Missing doses can cause the bacteria to become even more resistant, making it much harder to cure.
The Emotional Toll and Contagiousness
Being told you have a “superbug” or resistant TB can carry a heavy emotional toll and feelings of stigma. It is completely normal to feel overwhelmed. Because MDR-TB is a resistant strain, you will likely need to follow strict isolation guidelines initially to protect your family and community. However, as the new medications begin to work and your follow-up tests show the bacteria are clearing, your risk of transmitting the disease will decrease. Always follow your doctor’s specific guidance on when it is safe to interact with others again.
Common questions in this guide
Is multidrug-resistant tuberculosis (MDR-TB) curable?
What is the BPaLM regimen for MDR-TB?
What are the side effects of linezolid?
Why do I need an ECG while taking bedaquiline?
How long do I need to isolate with MDR-TB?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I a candidate for the six-month BPaL or BPaLM all-oral regimen, or do I need a different treatment based on my specific drug resistance profile?
- 2.How often will I need blood tests or ECGs to monitor for side effects from medications like bedaquiline and linezolid?
- 3.If I start experiencing tingling or numbness in my hands or feet, what are the exact steps we will take to adjust my linezolid dose?
- 4.How long will I need to remain isolated to ensure I am no longer contagious to my family and community?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (18)
- 1
Efficacy and safety of treatment regimens for drug-resistant tuberculosis in different regions: a systematic review and meta-analysis.
Geng X, Zhang F, Liu R, et al.
BMC infectious diseases 2026; (26(1)):361 doi:10.1186/s12879-026-12642-x.
PMID: 41566231 - 2
Update on drug treatments for multidrug resistant tuberculosis.
Davies GR, Aston S
Current opinion in infectious diseases 2023; (36(2)):132-139 doi:10.1097/QCO.0000000000000899.
PMID: 36718913 - 3
Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study.
Lecai J, Mijiti P, Chuangyue H, et al.
Frontiers in public health 2023; (11()):1134938 doi:10.3389/fpubh.2023.1134938.
PMID: 37408751 - 4
High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
Souleymane MB, Piubello A, Lawan IM, et al.
The European respiratory journal 2021; (57(1)) doi:10.1183/13993003.02250-2020.
PMID: 32703777 - 5
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z, Ahmad N, Baghaei P, et al.
The Lancet. Respiratory medicine 2020; (8(4)):383-394 doi:10.1016/S2213-2600(20)30047-3.
PMID: 32192585 - 6
Impact of Patient-Centered Care on Treatment Outcomes of Multidrug-Resistant/Rifampicin-Resistant Tuberculosis in Xi'an.
Luo H, Ma J, He X, et al.
Infection and drug resistance 2025; (18()):1425-1437 doi:10.2147/IDR.S484268.
PMID: 40098714 - 7
Effect of Cost-Exemption Policy on Treatment Interruption in Patients With Newly Diagnosed Pulmonary Tuberculosis in South Korea.
Lee SC, Lee JK, Ji HW, et al.
International journal of health policy and management 2024; (13()):8262.
PMID: 39099483 - 8
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment.
Nyang'wa BT, Motta I, Moodliar R, et al.
Nature communications 2026; (17(1)).
PMID: 42270675 - 9
Update of drug-resistant tuberculosis treatment guidelines: A turning point.
Vanino E, Granozzi B, Akkerman OW, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; (130 Suppl 1()):S12-S15 doi:10.1016/j.ijid.2023.03.013.
PMID: 36918080 - 10
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
Chesov D, Heyckendorf J, Alexandru S, et al.
The European respiratory journal 2021; (57(6)) doi:10.1183/13993003.02544-2020.
PMID: 33334942 - 11
Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
Decroo T, Aung KJM, Hossain MA, et al.
The European respiratory journal 2022; (59(3)) doi:10.1183/13993003.02124-2021.
PMID: 34561288 - 12
Effectiveness and safety of the BPaL regimen in the Philippines.
Flores I, Quelapio MI, Cabalitan C, et al.
Journal of clinical tuberculosis and other mycobacterial diseases 2025; (41()):100567 doi:10.1016/j.jctube.2025.100567.
PMID: 41146647 - 13
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Bigelow KM, Tasneen R, Chang YS, et al.
Antimicrobial agents and chemotherapy 2020; (64(10)) doi:10.1128/AAC.01178-20.
PMID: 32690647 - 14
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, et al.
The New England journal of medicine 2022; (387(9)):810-823 doi:10.1056/NEJMoa2119430.
PMID: 36053506 - 15
Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.
Fu L, Shi H, Sun F, et al.
BMC infectious diseases 2026; (26(1)).
PMID: 41735928 - 16
Linezolid for the treatment of drug-resistant tuberculosis.
Lange C, Barry C, Sotgiu G
The European respiratory journal 2025; (66(2)) doi:10.1183/13993003.00927-2025.
PMID: 40846488 - 17
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
Song Y, Shu W, Pei Y, et al.
BMC medicine 2024; (22(1)):401 doi:10.1186/s12916-024-03633-3.
PMID: 39300460 - 18
Real-world effectiveness and safety of prolonged bedaquiline course in the treatment of drug-resistant tuberculosis-a multi-center retrospective cohort study in a country with a high burden of drug-resistant tuberculosis.
Yu Y, Cao J, Pan H, et al.
Microbiology spectrum 2025; (13(8)):e0009725 doi:10.1128/spectrum.00097-25.
PMID: 40621913
This information about MDR-TB treatments is for educational purposes only. Always consult your infectious disease specialist or pulmonologist to determine the safest and most effective medication regimen for your specific resistance profile.
Get notified when new evidence is published on Tuberculosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.